Safety, Tolerability and Effects of Mannitol in Parkinson's Disease

Inclusion Criteria:

1. Ability to understand and signing of informed consent form.

2. Age 40-75 years at the day of visit 1.

3. Diagnosis of Parkinson's disease that is based on the United Kingdom brain bankcriteria diagnosed after the age of 40.

4. Stable regime of anti-parkinsonian medication for at least 4 weeks at the day of visit

Exclusion Criteria:

1. Patients with motor deficits that require administration of symptomatic therapy morethan 4 times per day at the day of visit 1.

2. Patients on advanced therapy for Parkinson's disease (sub-cutaneous apomorphine, deepbrain stimulation or intra-jejunal levodopa infusion).

3. Patients with dementia reflected by a Mini-mental state examination (MoCA) ≥ 24.

4. Patient with legal guardian.

5. History of psychosis or use of dopamine receptor blocking agent on the year proceedingat the visit 1. Quetiapine at dose lower or equal 50 mg per day prescribed forindication other than psychosis is allowed.

6. Suspected Parkinsonian syndrome other than Parkinson's disease.

7. Use of medical marihuana on the month proceeding visit 1.

8. Pregnant or lactating women, or fertile woman who does not use contraceptive. Woman ofchild-bearing potential must have a negative urine Human chorionic gonadotropin (hCG)and will be monitored by repeated urine tests.

9. Patient with significantly impaired renal functions (urea or creatinine values 20%above the upper norm limit).

10. Diabetes mellitus.

11. Clinical evidence for congestive heart failure.

12. Patient with symptomatic orthostatic hypotension.

13. Based on investigator's opinion, any medical condition that may progress due toconsumption of oral mannitol or glucose.